Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience
(1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/649 |
| _version_ | 1797318976572751872 |
|---|---|
| author | Lea Galunic Bilic Fedor Santek Zdravko Mitrovic Sandra Basic-Kinda Dino Dujmovic Marijo Vodanovic Inga Mandac Smoljanovic Slobodanka Ostojic Kolonic Ruzica Galunic Cicak Igor Aurer |
| author_facet | Lea Galunic Bilic Fedor Santek Zdravko Mitrovic Sandra Basic-Kinda Dino Dujmovic Marijo Vodanovic Inga Mandac Smoljanovic Slobodanka Ostojic Kolonic Ruzica Galunic Cicak Igor Aurer |
| author_sort | Lea Galunic Bilic |
| collection | DOAJ |
| description | (1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2003 and 2020 were retrospectively evaluated. There were 69 patients (49%) treated with IFRT, and 71 (51%) patients treated with ISRT. The median dose in the IFRT group was 36 Gy, (range 4–50.4 Gy), and in the ISRT group, it was 30 Gy (range 4–48 Gy). (3) Results: The median follow-up in the IFRT group was 133 months (95% CI 109–158), and in the ISRT group, it was 48 months (95% CI 39–57). In the IFRT group, locoregional control was 67%, and in the ISRT group, 73%. The 2- and 5-year overall survival (OS) in the IFRT and ISRT groups were 79% and 69% vs. 80% and 70%, respectively (<i>p</i> = 0.711). The 2- and 5-year event-free survival (EFS) in the IFRT and ISRT groups were 73% and 68% vs. 77% and 70%, respectively (<i>p</i> = 0.575). Acute side effects occurred in 43 (31%) patients, which is more frequent in the IFRT group, 34 (39%) patients, than in the ISRT group, 9 (13%) patients, <i>p</i> > 0.01. Late toxicities occurred more often in the IFRT group of patients, (10/53) 19%, than in the ISRT group of patients, (2/37) 5%, (<i>p</i> = 0.026). (4) Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised. |
| first_indexed | 2024-03-08T04:00:10Z |
| format | Article |
| id | doaj.art-fa3dae2868e34ef0bf76105b6e373973 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T04:00:10Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fa3dae2868e34ef0bf76105b6e3739732024-02-09T15:09:28ZengMDPI AGCancers2072-66942024-02-0116364910.3390/cancers16030649Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre ExperienceLea Galunic Bilic0Fedor Santek1Zdravko Mitrovic2Sandra Basic-Kinda3Dino Dujmovic4Marijo Vodanovic5Inga Mandac Smoljanovic6Slobodanka Ostojic Kolonic7Ruzica Galunic Cicak8Igor Aurer9Department of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, CroatiaDepartment of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, CroatiaSchool of Medicine, University of Zagreb, 10000 Zagreb, CroatiaDivision of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, CroatiaDivision of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, CroatiaDivision of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, CroatiaDivision of Haematology, Department of Internal Medicine, Clinical Hospital Merkur, 10000 Zagreb, CroatiaSchool of Medicine, University of Zagreb, 10000 Zagreb, CroatiaDepartment of Radiology, University Hospital Centre Zagreb, 10000 Zagreb, CroatiaSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia(1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2003 and 2020 were retrospectively evaluated. There were 69 patients (49%) treated with IFRT, and 71 (51%) patients treated with ISRT. The median dose in the IFRT group was 36 Gy, (range 4–50.4 Gy), and in the ISRT group, it was 30 Gy (range 4–48 Gy). (3) Results: The median follow-up in the IFRT group was 133 months (95% CI 109–158), and in the ISRT group, it was 48 months (95% CI 39–57). In the IFRT group, locoregional control was 67%, and in the ISRT group, 73%. The 2- and 5-year overall survival (OS) in the IFRT and ISRT groups were 79% and 69% vs. 80% and 70%, respectively (<i>p</i> = 0.711). The 2- and 5-year event-free survival (EFS) in the IFRT and ISRT groups were 73% and 68% vs. 77% and 70%, respectively (<i>p</i> = 0.575). Acute side effects occurred in 43 (31%) patients, which is more frequent in the IFRT group, 34 (39%) patients, than in the ISRT group, 9 (13%) patients, <i>p</i> > 0.01. Late toxicities occurred more often in the IFRT group of patients, (10/53) 19%, than in the ISRT group of patients, (2/37) 5%, (<i>p</i> = 0.026). (4) Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised.https://www.mdpi.com/2072-6694/16/3/649non-Hodgkin’s lymphomaradiotherapycombined modality therapysurvivallate complications |
| spellingShingle | Lea Galunic Bilic Fedor Santek Zdravko Mitrovic Sandra Basic-Kinda Dino Dujmovic Marijo Vodanovic Inga Mandac Smoljanovic Slobodanka Ostojic Kolonic Ruzica Galunic Cicak Igor Aurer Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience Cancers non-Hodgkin’s lymphoma radiotherapy combined modality therapy survival late complications |
| title | Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience |
| title_full | Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience |
| title_fullStr | Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience |
| title_full_unstemmed | Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience |
| title_short | Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience |
| title_sort | long term results of ifrt vs isrt in infradiaphragmal fields in aggressive non hodgkins s lymphoma patients a single centre experience |
| topic | non-Hodgkin’s lymphoma radiotherapy combined modality therapy survival late complications |
| url | https://www.mdpi.com/2072-6694/16/3/649 |
| work_keys_str_mv | AT leagalunicbilic longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT fedorsantek longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT zdravkomitrovic longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT sandrabasickinda longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT dinodujmovic longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT marijovodanovic longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT ingamandacsmoljanovic longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT slobodankaostojickolonic longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT ruzicagaluniccicak longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience AT igoraurer longtermresultsofifrtvsisrtininfradiaphragmalfieldsinaggressivenonhodgkinsslymphomapatientsasinglecentreexperience |